Trial Profile
A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Edoxaban (Primary) ; Enoxaparin sodium; Heparin; Low molecular weight heparins; Warfarin
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms Hokusai-VTE
- Sponsors Daiichi Sankyo Inc
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Results obtaining the outcomes from CARAVAGGIO, HOKUSAI-VTE, ADAM VTE and SELECT-D and analysing Cost-effectiveness of apixaban versus other direct oral anticoagulants and low-molecular-weight-heparins for cancer associated venous thromboembolism, presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 04 Dec 2018 Results of post hoc analysis evaluating the risk of recurrent VTE during anticoagulation with heparin, edoxaban or warfarin and to identify predictors of recurrence, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.